伊布替尼治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者干细胞移植前后
伊布替尼在自体干细胞移植期间和之后对比安慰剂治疗复发或难治性弥漫性大 B 细胞淋巴瘤(活化 B 细胞亚型)患者的随机双盲 III 期研究
This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Before transplant, stem cells are taken from patients and stored. Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Ibrutinib is a drug that may stop the growth of cancer cells by blocking a protein that is needed for cell growth. It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.
研究概览
地位
详细说明
PRIMARY OBJECTIVE:
I. To evaluate the ability of ibrutinib to improve 24-month progression free survival (PFS) compared to placebo in patients with non-germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) as determined by immunohistochemistry (IHC).
SECONDARY OBJECTIVES:
I. To evaluate the ability of ibrutinib to improve overall survival (OS) compared to placebo.
II. To evaluate the ability of ibrutinib to improve progression free survival (PFS) compared to placebo.
III. To evaluate the ability of ibrutinib to improve post-transplant response rates compared to placebo.
IV. To evaluate time to hematopoietic recovery in the two arms. V. To evaluate the safety and tolerability of ibrutinib compared to placebo. VI. To evaluate the incidence of secondary malignancies in the two arms. VII. To evaluate immune reconstitution in the two arms.
CORRELATIVE SCIENCE OBJECTIVES:
I. To assess whether pre-autologous hematopoietic stem cell transplantation (AutoHCT) positive fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) is associated with inferior 24-month PFS as well as PFS and OS.
II. To assess whether pre-AutoHCT FDG-PET results are differentially associated with 24-month PFS, PFS and OS in the ibrutinib versus placebo arms.
III. To evaluate the application of the Lugano criteria and change in quantitative measurements between pre-AutoHCT and post AutoHCT (e.g. delta standard uptake variable [SUV], %SUV decline and %metabolic tumor volume [MTV] decline, and other available applicable quantitative measurements) to assess the association between changes in these variables and outcomes, such as PFS and OS.
IV. To assess whether the GSTT1 null polymorphism is correlated with pulmonary toxicity after BCNU (carmustine)-containing conditioning regimens as part of autologous stem cell transplantation.
V. To assess whether other polymorphisms in the BCNU metabolism pathway or BCNU damage repair pathway(s) are associated with pulmonary toxicity after BCNU-containing conditioning regimens as part of autologous stem cell transplantation.
VI. To evaluate whether any of the proposed deoxyribonucleic acid (DNA) polymorphisms are associated with other toxicities.
VII. To assess whether DLBCL subtype based on the lymphoma subtyping test (LST) is associated with 24-month PFS, PFS, and OS with ibrutinib compared to placebo in patients treated on this protocol.
VIII. To assess whether activating mutations in the BCR pathway are associated with response to ibrutinib and with clinical outcomes in patients treated on this protocol.
IX. To assess whether there are any phenotypic associations with IHC markers (particularly MYC protein expression level) and presence of these mutations.
X. To assess whether BCL2, MYC, and Ki67 expression by IHC affect clinical outcomes in patients treated on this protocol.
XI. To assess whether translocations in MYC with or without BCL2 and BC6 have poor outcomes in patients treated on this protocol and whether ibrutinib modifies the prognosis.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
CONDITIONING REGIMEN:
ARM I: Investigators may choose to use either the BEAMi (carmustine, etoposide, cytarabine, melphalan, ibrutinib) or CBVi (cyclophosphamide, carmustine, etoposide, ibrutinib) regimen.
BEAMi: Patients receive ibrutinib orally (PO) on days -6 to -1, carmustine intravenously (IV) over 2 hours on day -6, etoposide IV twice daily (BID) over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1. Optionally, if a day of rest is planned, patients may receive BEAMi on days -7 to -2.
CBVi: Patients receive ibrutinib PO on days -6 to -1, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Optionally, if a day of rest is planned, patients may receive CBVi on days -7 to -2.
ARM II: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I.
TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0.
CONTINUATION REGIMEN:
ARM I: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I.
After completion of treatment, patients are followed up every 6 months for up to 60 months from registration.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Riyadh、沙特阿拉伯、11211
- King Faisal Specialist Hospital and Research Centre
-
-
-
-
Alaska
-
Anchorage、Alaska、美国、98508
- Anchorage Associates in Radiation Medicine
-
Anchorage、Alaska、美国、99508
- Alaska Breast Care and Surgery LLC
-
Anchorage、Alaska、美国、99508
- Alaska Oncology and Hematology LLC
-
Anchorage、Alaska、美国、99508
- Alaska Women's Cancer Care
-
Anchorage、Alaska、美国、99508
- Anchorage Oncology Centre
-
Anchorage、Alaska、美国、99508
- Katmai Oncology Group
-
Anchorage、Alaska、美国、99508
- Providence Alaska Medical Center
-
Anchorage、Alaska、美国、99504
- Anchorage Radiation Therapy Center
-
Fairbanks、Alaska、美国、99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Tucson、Arizona、美国、85719
- Banner University Medical Center - Tucson
-
Tucson、Arizona、美国、85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Burbank、California、美国、91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Duarte、California、美国、91010
- City of Hope Comprehensive Cancer Center
-
La Jolla、California、美国、92093
- UC San Diego Moores Cancer Center
-
Loma Linda、California、美国、92354
- Loma Linda University Medical Center
-
Los Angeles、California、美国、90048
- Cedars-Sinai Medical Center
-
Orange、California、美国、92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Sacramento、California、美国、95817
- University of California Davis Comprehensive Cancer Center
-
San Francisco、California、美国、94143
- UCSF Medical Center-Parnassus
-
-
Colorado
-
Aurora、Colorado、美国、80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora、Colorado、美国、80012
- The Medical Center of Aurora
-
Aurora、Colorado、美国、80045
- UCHealth University of Colorado Hospital
-
Boulder、Colorado、美国、80303
- Boulder Community Foothills Hospital
-
Boulder、Colorado、美国、80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs、Colorado、美国、80909
- UCHealth Memorial Hospital Central
-
Denver、Colorado、美国、80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver、Colorado、美国、80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver、Colorado、美国、80220
- Rocky Mountain Cancer Centers-Rose
-
Denver、Colorado、美国、80204
- Denver Health Medical Center
-
Denver、Colorado、美国、80218
- Colorado Blood Cancer Institute
-
Denver、Colorado、美国、80209
- The Women's Imaging Center
-
Denver、Colorado、美国、80206
- National Jewish Health-Main Campus
-
Denver、Colorado、美国、80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Englewood、Colorado、美国、80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood、Colorado、美国、80113
- Swedish Medical Center
-
Fort Collins、Colorado、美国、80524
- Poudre Valley Hospital
-
Golden、Colorado、美国、80401
- National Jewish Health-Western Hematology Oncology
-
Grand Junction、Colorado、美国、81501
- Saint Mary's Hospital and Regional Medical Center
-
Grand Junction、Colorado、美国、81505
- Grand Valley Oncology
-
Greeley、Colorado、美国、80631
- Banner North Colorado Medical Center
-
Lafayette、Colorado、美国、80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Littleton、Colorado、美国、80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree、Colorado、美国、80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland、Colorado、美国、80539
- Banner North Colorado Medical Center - Loveland Campus
-
Wheat Ridge、Colorado、美国、80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
New Haven、Connecticut、美国、06520
- Yale University
-
New Haven、Connecticut、美国、06510
- Smilow Cancer Center/Yale-New Haven Hospital
-
-
Delaware
-
Lewes、Delaware、美国、19958
- Beebe Medical Center
-
Newark、Delaware、美国、19713
- Helen F Graham Cancer Center
-
Newark、Delaware、美国、19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark、Delaware、美国、19713
- Medical Oncology Hematology Consultants PA
-
Newark、Delaware、美国、19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach、Delaware、美国、19971
- Beebe Health Campus
-
Seaford、Delaware、美国、19973
- TidalHealth Nanticoke / Allen Cancer Center
-
Wilmington、Delaware、美国、19801
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Deerfield Beach、Florida、美国、33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Gainesville、Florida、美国、32610
- UF Health Cancer Institute - Gainesville
-
Miami、Florida、美国、33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation、Florida、美国、33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa、Florida、美国、33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta、Georgia、美国、30342
- Northside Hospital
-
Augusta、Georgia、美国、30912
- Augusta University Medical Center
-
-
Idaho
-
Boise、Idaho、美国、83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise、Idaho、美国、83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell、Idaho、美国、83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene、Idaho、美国、83814
- Kootenai Health - Coeur d'Alene
-
Fruitland、Idaho、美国、83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian、Idaho、美国、83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa、Idaho、美国、83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa、Idaho、美国、83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls、Idaho、美国、83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint、Idaho、美国、83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls、Idaho、美国、83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Northwestern University
-
Chicago、Illinois、美国、60637
- University of Chicago Comprehensive Cancer Center
-
Chicago、Illinois、美国、60612
- University of Illinois
-
Chicago、Illinois、美国、60612
- Rush MD Anderson Cancer Center
-
Maywood、Illinois、美国、60153
- Loyola University Medical Center
-
New Lenox、Illinois、美国、60451
- UC Comprehensive Cancer Center at Silver Cross
-
-
Kansas
-
Chanute、Kansas、美国、66720
- Cancer Center of Kansas - Chanute
-
Dodge City、Kansas、美国、67801
- Cancer Center of Kansas - Dodge City
-
El Dorado、Kansas、美国、67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott、Kansas、美国、66701
- Cancer Center of Kansas - Fort Scott
-
Independence、Kansas、美国、67301
- Cancer Center of Kansas-Independence
-
Kansas City、Kansas、美国、66160
- University of Kansas Cancer Center
-
Kingman、Kansas、美国、67068
- Cancer Center of Kansas-Kingman
-
Lawrence、Kansas、美国、66044
- Lawrence Memorial Hospital
-
Liberal、Kansas、美国、67905
- Cancer Center of Kansas-Liberal
-
Manhattan、Kansas、美国、66502
- Cancer Center of Kansas-Manhattan
-
McPherson、Kansas、美国、67460
- Cancer Center of Kansas - McPherson
-
Newton、Kansas、美国、67114
- Cancer Center of Kansas - Newton
-
Parsons、Kansas、美国、67357
- Cancer Center of Kansas - Parsons
-
Pratt、Kansas、美国、67124
- Cancer Center of Kansas - Pratt
-
Salina、Kansas、美国、67401
- Cancer Center of Kansas - Salina
-
Wellington、Kansas、美国、67152
- Cancer Center of Kansas - Wellington
-
Westwood、Kansas、美国、66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita、Kansas、美国、67214
- Ascension Via Christi Hospitals Wichita
-
Wichita、Kansas、美国、67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita、Kansas、美国、67214
- Cancer Center of Kansas - Wichita
-
Wichita、Kansas、美国、67208
- Associates In Womens Health
-
Winfield、Kansas、美国、67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Louisville、Kentucky、美国、40202
- The James Graham Brown Cancer Center at University of Louisville
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70806
- Baton Rouge General Medical Center
-
Baton Rouge、Louisiana、美国、70809
- Hematology/Oncology Clinic PLLC
-
New Orleans、Louisiana、美国、70112
- Tulane University School of Medicine
-
New Orleans、Louisiana、美国、70121
- Ochsner Medical Center Jefferson
-
Shreveport、Louisiana、美国、71103
- LSU Health Sciences Center at Shreveport
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Fitchburg、Massachusetts、美国、01420
- Simonds-Sinon Regional Cancer Center
-
Worcester、Massachusetts、美国、01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- University of Michigan Rogel Cancer Center
-
Battle Creek、Michigan、美国、49017
- Bronson Battle Creek
-
Detroit、Michigan、美国、48201
- Wayne State University/Karmanos Cancer Institute
-
Grand Rapids、Michigan、美国、49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids、Michigan、美国、49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo、Michigan、美国、49007
- West Michigan Cancer Center
-
Kalamazoo、Michigan、美国、49007
- Bronson Methodist Hospital
-
Kalamazoo、Michigan、美国、49009
- Beacon Kalamazoo Cancer Center
-
Kalamazoo、Michigan、美国、49048
- Beacon Kalamazoo
-
Muskegon、Michigan、美国、49444
- Trinity Health Muskegon Hospital
-
Niles、Michigan、美国、49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores、Michigan、美国、49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City、Michigan、美国、49677
- Corewell Health Reed City Hospital
-
Saint Joseph、Michigan、美国、49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph、Michigan、美国、49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City、Michigan、美国、49684
- Munson Medical Center
-
Wyoming、Michigan、美国、49519
- University of Michigan Health - West
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55455
- University of Minnesota/Masonic Cancer Center
-
Rochester、Minnesota、美国、55905
- Mayo Clinic in Rochester
-
-
Missouri
-
Creve Coeur、Missouri、美国、63141
- Siteman Cancer Center at West County Hospital
-
St Louis、Missouri、美国、63110
- Washington University School of Medicine
-
St Louis、Missouri、美国、63129
- Siteman Cancer Center-South County
-
St Louis、Missouri、美国、63104
- SSM Health Saint Louis University Hospital
-
-
Montana
-
Anaconda、Montana、美国、59711
- Community Hospital of Anaconda
-
Billings、Montana、美国、59101
- Billings Clinic Cancer Center
-
Billings、Montana、美国、59101
- Saint Vincent Healthcare
-
Billings、Montana、美国、59102
- Saint Vincent Frontier Cancer Center
-
Bozeman、Montana、美国、59715
- Bozeman Health Deaconess Hospital
-
Great Falls、Montana、美国、59405
- Great Falls Clinic
-
Great Falls、Montana、美国、59405
- Benefis Sletten Cancer Institute
-
Helena、Montana、美国、59601
- Saint Peter's Community Hospital
-
Kalispell、Montana、美国、59901
- Logan Health Medical Center
-
Missoula、Montana、美国、59802
- Saint Patrick Hospital - Community Hospital
-
Missoula、Montana、美国、59804
- Community Medical Center
-
-
Nebraska
-
Bellevue、Nebraska、美国、68123
- Nebraska Medicine-Bellevue
-
Omaha、Nebraska、美国、68198
- University of Nebraska Medical Center
-
Omaha、Nebraska、美国、68118
- Nebraska Medicine-Village Pointe
-
-
New Hampshire
-
Lebanon、New Hampshire、美国、03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New York
-
Buffalo、New York、美国、14263
- Roswell Park Cancer Institute
-
New York、New York、美国、10065
- NYP/Weill Cornell Medical Center
-
Oswego、New York、美国、13126
- Upstate Cancer Center at Oswego
-
Rochester、New York、美国、14642
- University of Rochester
-
Syracuse、New York、美国、13210
- State University of New York Upstate Medical University
-
The Bronx、New York、美国、10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx、New York、美国、10467
- Children's Hospital at Montefiore
-
The Bronx、New York、美国、10467
- Montefiore Medical Center - Moses Campus
-
The Bronx、New York、美国、10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599
- UNC Lineberger Comprehensive Cancer Center
-
Durham、North Carolina、美国、27710
- Duke University Medical Center
-
Winston-Salem、North Carolina、美国、27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland、Ohio、美国、44106
- Case Western Reserve University
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic Foundation
-
Columbus、Ohio、美国、43210
- Ohio State University Comprehensive Cancer Center
-
West Chester、Ohio、美国、45069
- University of Cincinnati Cancer Center-West Chester
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Bend、Oregon、美国、97701
- Saint Charles Health System
-
Clackamas、Oregon、美国、97015
- Clackamas Radiation Oncology Center
-
Clackamas、Oregon、美国、97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay、Oregon、美国、97420
- Bay Area Hospital
-
Newberg、Oregon、美国、97132
- Providence Newberg Medical Center
-
Ontario、Oregon、美国、97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City、Oregon、美国、97045
- Providence Willamette Falls Medical Center
-
Portland、Oregon、美国、97239
- Oregon Health and Science University
-
Portland、Oregon、美国、97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland、Oregon、美国、97213
- Providence Portland Medical Center
-
Portland、Oregon、美国、97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Chadds Ford、Pennsylvania、美国、19317
- Christiana Care Health System-Concord Health Center
-
Danville、Pennsylvania、美国、17822
- Geisinger Medical Center
-
Hazleton、Pennsylvania、美国、18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Lewisburg、Pennsylvania、美国、17837
- Geisinger Medical Oncology-Lewisburg
-
Lewistown、Pennsylvania、美国、17044
- Lewistown Hospital
-
Philadelphia、Pennsylvania、美国、19111
- Fox Chase Cancer Center
-
Pittsburgh、Pennsylvania、美国、15232
- UPMC Hillman Cancer Center
-
Pottsville、Pennsylvania、美国、17901
- Geisinger Cancer Services-Pottsville
-
Scranton、Pennsylvania、美国、18510
- Community Medical Center
-
Selinsgrove、Pennsylvania、美国、17870
- Geisinger Medical Oncology-Selinsgrove
-
State College、Pennsylvania、美国、16801
- Geisinger Medical Group
-
Wilkes-Barre、Pennsylvania、美国、18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Boiling Springs、South Carolina、美国、29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston、South Carolina、美国、29425
- Medical University of South Carolina
-
Clinton、South Carolina、美国、29325
- Prisma Health Cancer Institute - Laurens
-
Easley、South Carolina、美国、29640
- Prisma Health Cancer Institute - Easley
-
Greenville、South Carolina、美国、29605
- Prisma Health Cancer Institute - Faris
-
Greenville、South Carolina、美国、29607
- Saint Francis Cancer Center
-
Greenville、South Carolina、美国、29615
- Prisma Health Cancer Institute - Eastside
-
Greenville、South Carolina、美国、29605
- Prisma Health Cancer Institute - Butternut
-
Greenville、South Carolina、美国、29601
- Saint Francis Hospital
-
Greenville、South Carolina、美国、29605
- Prisma Health Greenville Memorial Hospital
-
Greer、South Carolina、美国、29650
- Prisma Health Cancer Institute - Greer
-
Seneca、South Carolina、美国、29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls、South Dakota、美国、57105
- Avera Cancer Institute
-
-
Tennessee
-
Franklin、Tennessee、美国、37067
- Vanderbilt-Ingram Cancer Center Cool Springs
-
Memphis、Tennessee、美国、38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
Nashville、Tennessee、美国、37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville、Tennessee、美国、37204
- Vanderbilt Breast Center at One Hundred Oaks
-
-
Texas
-
Houston、Texas、美国、77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
-
Utah
-
American Fork、Utah、美国、84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City、Utah、美国、84720
- Sandra L Maxwell Cancer Center
-
Farmington、Utah、美国、84025
- Farmington Health Center
-
Logan、Utah、美国、84321
- Logan Regional Hospital
-
Murray、Utah、美国、84107
- Intermountain Medical Center
-
Ogden、Utah、美国、84403
- McKay-Dee Hospital Center
-
Provo、Utah、美国、84604
- Utah Valley Regional Medical Center
-
Riverton、Utah、美国、84065
- Riverton Hospital
-
Salt Lake City、Utah、美国、84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City、Utah、美国、84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City、Utah、美国、84143
- LDS Hospital
-
South Jordan、Utah、美国、84009
- South Jordan Health Center
-
St. George、Utah、美国、84770
- Saint George Regional Medical Center
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- University of Virginia Cancer Center
-
Richmond、Virginia、美国、23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Aberdeen、Washington、美国、98520
- Providence Regional Cancer System-Aberdeen
-
Anacortes、Washington、美国、98221
- Cancer Care Center at Island Hospital
-
Bellingham、Washington、美国、98225
- PeaceHealth Saint Joseph Medical Center
-
Centralia、Washington、美国、98531
- Providence Regional Cancer System-Centralia
-
Edmonds、Washington、美国、98026
- Swedish Cancer Institute-Edmonds
-
Everett、Washington、美国、98201
- Providence Regional Cancer Partnership
-
Issaquah、Washington、美国、98029
- Swedish Cancer Institute-Issaquah
-
Kennewick、Washington、美国、99336
- Kadlec Clinic Hematology and Oncology
-
Lacey、Washington、美国、98503
- Providence Regional Cancer System-Lacey
-
Longview、Washington、美国、98632
- PeaceHealth Saint John Medical Center
-
Seattle、Washington、美国、98107
- Swedish Medical Center-Ballard Campus
-
Seattle、Washington、美国、98122
- Swedish Medical Center-First Hill
-
Seattle、Washington、美国、98195
- University of Washington Medical Center - Montlake
-
Seattle、Washington、美国、98112
- Kaiser Permanente Washington
-
Seattle、Washington、美国、98104
- Pacific Gynecology Specialists
-
Seattle、Washington、美国、98122-5711
- Swedish Medical Center-Cherry Hill
-
Seattle、Washington、美国、98109
- Fred Hutchinson Cancer Center
-
Shelton、Washington、美国、98584
- Providence Regional Cancer System-Shelton
-
Spokane、Washington、美国、99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane、Washington、美国、99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
Spokane Valley、Washington、美国、99216
- MultiCare Deaconess Cancer and Blood Specialty Center - Valley
-
Vancouver、Washington、美国、98664
- PeaceHealth Southwest Medical Center
-
Walla Walla、Washington、美国、99362
- Providence Saint Mary Regional Cancer Center
-
Yelm、Washington、美国、98597
- Providence Regional Cancer System-Yelm
-
-
Wisconsin
-
Burlington、Wisconsin、美国、53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chippewa Falls、Wisconsin、美国、54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire、Wisconsin、美国、54701
- Marshfield Medical Center-EC Cancer Center
-
Eau Claire、Wisconsin、美国、54701
- Marshfield Clinic Cancer Center at Sacred Heart
-
Fond du Lac、Wisconsin、美国、54937
- Aurora Health Center-Fond du Lac
-
Germantown、Wisconsin、美国、53022
- Aurora Health Care Germantown Health Center
-
Grafton、Wisconsin、美国、53024
- Aurora Cancer Care-Grafton
-
Green Bay、Wisconsin、美国、54311
- Aurora BayCare Medical Center
-
Kenosha、Wisconsin、美国、53142
- Aurora Cancer Care-Kenosha South
-
Ladysmith、Wisconsin、美国、54848
- Marshfield Medical Center - Ladysmith
-
Madison、Wisconsin、美国、53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette、Wisconsin、美国、54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield、Wisconsin、美国、54449
- Marshfield Medical Center-Marshfield
-
Marshfield、Wisconsin、美国、54449
- Marshfield Medical Center
-
Milwaukee、Wisconsin、美国、53226
- Medical College of Wisconsin
-
Milwaukee、Wisconsin、美国、53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee、Wisconsin、美国、53215
- Aurora Saint Luke's Medical Center
-
Milwaukee、Wisconsin、美国、53233
- Aurora Sinai Medical Center
-
Minocqua、Wisconsin、美国、54548
- Marshfield Medical Center - Minocqua
-
Oshkosh、Wisconsin、美国、54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine、Wisconsin、美国、53406
- Aurora Cancer Care-Racine
-
Rice Lake、Wisconsin、美国、54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan、Wisconsin、美国、53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point、Wisconsin、美国、54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit、Wisconsin、美国、53066
- Aurora Medical Center in Summit
-
Two Rivers、Wisconsin、美国、54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wausau、Wisconsin、美国、54401
- Marshfield Clinic-Wausau Center
-
Wauwatosa、Wisconsin、美国、53226
- Aurora Cancer Care-Milwaukee West
-
West Allis、Wisconsin、美国、53227
- Aurora West Allis Medical Center
-
Weston、Wisconsin、美国、54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids、Wisconsin、美国、54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Wyoming
-
Cheyenne、Wyoming、美国、82001
- Cheyenne Regional Medical Center-West
-
Cody、Wyoming、美国、82414
- Billings Clinic-Cody
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
PRE-REGISTRATION ELIGIBILITY CRITERIA (STEP 0)
-
Patients must have paraffin tissue from the diagnostic or relapse biopsy available to be submitted for central pathology review; this review is mandatory prior to registration to confirm eligibility and should be initiated as soon as possible
-
ELIGIBILITY CRITERIA (STEP 1)
-
Diagnosis of World Health Organization (WHO) diffuse large B-cell lymphoma, non-GCB by central review confirmation
-
Patient must be deemed eligible to proceed with high-dose chemotherapy and autologous stem cell transplantation by local transplant center
-
New York Heart Association class I or less; ordinary physical activity does not cause undue fatigue, palpitations, dyspnea, or angina pain; patients 60 years or older must have a left ventricular ejection fraction (LVEF) at rest >= 40% measured by echocardiogram or multi-gated acquisition (MUGA)
-
Diffusion capacity of the lung for carbon monoxide (DLCO) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
-
Forced expiratory volume in 1 second (FEV1) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
-
Forced vital capacity (FVC) >= 40% of predicted (corrected or uncorrected for hemoglobin per institutional standards)
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) unless isolated hyperbilirubinemia attributed to Gilbert's syndrome
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN)
-
Creatinine =< 2.0 mg/dL OR creatinine clearance (calculated clearance permitted) >= 40 mL/min by Cockcroft-Gault formula
-
Prothrombin time (PT)/ international normalized ration (INR) < 1.5 x ULN and partial thromboplastin time (PTT) (activated [a]PTT) < 1.5 x ULN
-
Patient must have progressed or be refractory to prior anthracycline-containing chemotherapy (e.g. rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone [R-CHOP], dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab [DA-EPOCH-R], etc)
-
No more than 3 prior regimens for large cell component (e.g. one induction and two salvage therapies); monoclonal antibody alone or involved field/involved site radiotherapy do not count as lines of therapy. Prior CART therapy is allowed and counts as one line of therapy
-
Prior use of ibrutinib is allowed unless patient has had disease progression while receiving ibrutinib
-
Patient must have chemosensitive disease as defined by at least a partial response to salvage therapy at their latest assessment
-
No major surgery =< 7 days prior to registration and no minor surgery =< 3 days prior to registration (with the exception of intravenous access placement, e.g. Hickman or peripherally inserted central catheter [PICC])
-
Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects; therefore, for women of childbearing potential only, a negative serum pregnancy test must be obtained within 14 days prior to registration
- Women of childbearing potential must use adequate contraception from study start to one month after the last dose of protocol therapy; adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method or total abstinence; men must practice complete abstinence or agree to use an adequate contraception method from study start to one month after the last dose of protocol therapy
-
Age >= 18 years
-
Patients should not require chronic use of strong CYP3A inhibitors or strong CYP3A inducers
-
Patients should not require concurrent therapeutic doses of steroids (> 20 mg of prednisone/day or equivalent) unless they need them for the indications; steroids should be discontinued for 14 days before starting protocol treatment
-
Human immunodeficiency virus (HIV) infected patients are eligible provided they meet all other eligibility criteria, and:
- There is no prior history of acquired immunodeficiency syndrome (AIDS) defining conditions other than historically low CD4+ T-cell count or B-cell lymphoma
- In the opinion of an expert in HIV disease, prospects for long-term survival are excellent were it not for the diagnosis of lymphoma
- Use of HIV protease inhibitors as part of the anti-HIV regimen OR as a pharmacologic booster is not allowed
- Zidovudine is not allowed
- Once daily combination pills for HIV containing a pharmacologic booster such as cobicistat are not allowed
- Patients with multi-drug resistant HIV are not eligible
-
Patients cannot have:
- Active central nervous system or meningeal involvement by lymphoma; patients with a history of central nervous system (CNS) or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced magnetic resonance imaging (MRI) imaging for at least 91 days prior to registration
- Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow biopsy prior to initiation of therapy
- A known bleeding diathesis
- Requirement for warfarin or similar vitamin K antagonists; these drugs are prohibited 28 days prior to the first treatment and throughout the trial
- History of stroke or intracranial hemorrhage =< 6 months before treatment
- Currently active, clinically significant hepatic impairment (Child-Pugh class B or C according to the Child Pugh classification
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
- Serologic status reflecting active hepatitis B or C infection; patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment; (PCR positive patients will be excluded)
-
Eastern Cooperative Oncology Group (ECOG) performance status must be =< 2
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm I (ibrutinib, chemotherapy, autoHCT)
CONDITIONING REGIMEN: Investigators may choose to use either the BEAMi or CBVi regimen. BEAMi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV BID over 1-2 hours and cytarabine IV BID over 1-2 hours on days -5 to -2, and melphalan IV over 20-30 minutes on day -1. CBVi: Patients receive ibrutinib PO on days -6 to -1 or days -7 to -2 if a day of rest is planned, carmustine IV over 2 hours on day -6, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. TRANSPLANT: In both arms, patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0. CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive ibrutinib PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
其他名称:
Given IV
其他名称:
Given PO
其他名称:
Given IV
其他名称:
Given IV
其他名称:
Correlative studies
其他名称:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
其他名称:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
其他名称:
Given IV
其他名称:
|
|
安慰剂比较:Arm II (placebo, chemotherapy, autoHCT)
CONDITIONING REGIMEN: Patients receive placebo PO on days -6 to -1 and receive 1 of the 2 conditioning regimens as in Arm I. TRANSPLANT: Patients undergo autologous hematopoietic progenitor cell or bone marrow transplant on day 0. CONTINUATION REGIMEN: Beginning 30-60 days after transplant, patients receive placebo PO on days 1-28. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover Arm I. |
Correlative studies Given IV
其他名称:
Given IV
其他名称:
Given PO Given IV
其他名称:
Given IV
其他名称:
Correlative studies
其他名称:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
其他名称:
Undergo autologous hematopoietic progenitor cells or bone marrow transplant
其他名称:
Given IV
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
24-month Progression-free Survival (PFS), Defined as the Proportion of Patients Who Are Alive and Progression-free 2 Years From Randomization
大体时间:Time between registration and disease progression or death, whichever comes first, assessed at 24 months
|
Will be assessed using the Lugano classification. |
Time between registration and disease progression or death, whichever comes first, assessed at 24 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival (OS)
大体时间:The time between randomization and death from any cause, assessed up to 5 years (60 months)
|
For each arm, the distribution of OS will be estimated using the Kaplan-Meier method. OS will be compared between the two arms using the log-rank test and Cox regression method adjusting for the known predictors. |
The time between randomization and death from any cause, assessed up to 5 years (60 months)
|
|
Time to Hematopoietic Engraftment
大体时间:First day of one week without platelet transfusion, assessed up to 5 years
|
Will be defined as platelet count greater than or equal to 20,000/uL following nadir. |
First day of one week without platelet transfusion, assessed up to 5 years
|
|
PFS
大体时间:Time between registration and disease progression or death, whichever comes first, assessed up to 5 years (60 months)
|
For each arm, the distribution of PFS will be estimated using the Kaplan-Meier method. PFS will be compared between the two arms using the log-rank test and Cox regression method adjusting for the known predictors. |
Time between registration and disease progression or death, whichever comes first, assessed up to 5 years (60 months)
|
|
Response Rate Using the Lugano Classification
大体时间:Up to 60 months
|
The metabolic response proportion following AutoHCT will be compared between the two arms using chi-squared test. |
Up to 60 months
|
|
Treatment-related Mortality
大体时间:Up to 60 months
|
Treatment-related mortality will be summarized using contingency tables. |
Up to 60 months
|
|
Incidence of Hematologic Toxicity of Ibrutinib Therapy
大体时间:Up to 60 months
|
Hematologic toxicity will be summarized using contingency tables. |
Up to 60 months
|
|
Incidence of Secondary Malignancies
大体时间:Up to 60 months
|
Incidence of secondary malignancies will be summarized using contingency tables. |
Up to 60 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Fludeoxyglucose Positron Emission Tomography (FDG-PET) Imaging Results
大体时间:Baseline
|
PFS and OS will be compared between PET/computed tomography (CT) positive and negative groups using the two-sample log-rank test with a 2-sided alpha of 5%. A Cox regression model will be conducted to regress PFS and OS on PET/CT positivity. Deauville criteria analyses will be conducted with cutoffs at scores of 2 and 3, and quantitative measurements, e.g. delta standard uptake value (SUV), %SUV decline and %MTV decline, in place of the dichotomous FDG-PET/CT outcome. Positive/negative predictive values, sensitivity and specificity of PET/CT further estimated by dichotomizing the PFS and OS at 2 years. |
Baseline
|
|
GSTT1 Null Allele Expression
大体时间:Baseline
|
GSTT1 null allele expression will be associated with carmustine toxicity. Quantified using the standard Common Terminology Criteria for Adverse Events and changes in diffusing capacity of the lungs for carbon monoxide from baseline. |
Baseline
|
|
Single-nuclear Polymorphisms (SNPs) in the BCNU Metabolism or Damage Repair Pathways
大体时间:Baseline
|
All SNPs will be evaluated for deviation from Hardy-Weinberg. In the absence of a hypothesized effect, analyses will be powered for allele dosing (i.e., additive) effects. The Cochran-Armitage test (for binary endpoints), Jonkheere-Terpstra test (for quantitative traits including biomarker or gene expressions in serum or tumor ribonucleic acid) and the Cox score test (for censored time-to-event outcomes) will be used to quantify marginal associations. Multivariable models, with molecular, clinical and demographic variables, will be constructed using conditional inference trees and random forests. |
Baseline
|
|
BCR Pathway Mutations
大体时间:Baseline
|
The mutation of CD79a/b, caspase recruitment domain family, member 11 (CARD11), tumor necrosis factor, alpha-induced protein 3 TNFAIP3), and myeloid differentiation primary response 88 (MYD88) will be associated with each outcome in the ibrutinib arm (Arm A) using the chi-squared test for response rate and the log-rank test for each censored outcome. Similar analyses will be conducted for the placebo arm (Arm B) to show that the association between mutation and the outcomes observed in the ibrutinib arm is not observed in the placebo arm. |
Baseline
|
|
BCL2, MYC, and Ki67 Expression in Tissue Samples by Immunohistochemistry (IHC)
大体时间:Baseline
|
The expression of BCL2, MYC, and Ki67 will be analyzed to assess whether they affect clinical outcomes. |
Baseline
|
|
MYC Translocations
大体时间:Baseline
|
Translocations in MYC with or without BCL2, and BCL6 will be analyzed to determine whether they are related to poor outcomes and whether ibrutinib modifies the prognosis. |
Baseline
|
合作者和调查者
调查人员
- 首席研究员:Charalambos B Andreadis、Alliance for Clinical Trials in Oncology
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 氨基酸,肽和蛋白质
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 调查技术
- 疗法
- 临床实验室技术
- 诊断技术和程序
- 诊断
- 手术程序,手术
- 核酸,核苷酸和核苷
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- Podophyllotoxin
- 四氢乙烯甲烯烃
- 萘
- 多环芳烃
- 碳氢化合物,芳香族
- 多环化合物
- 葡萄糖剂
- 糖苷
- 移植
- 酰胺
- 氨基酸
- 胞苷
- 嘧啶核苷
- 嘧啶
- 卫生服务
- 医疗机构的劳动力和服务
- 预防保健服务
- 磷酰胺芥末
- 氮芥末化合物
- 芥末化合物
- 碳氢化合物,卤素
- 磷酰胺
- 有机磷化合物
- 核苷
- 阿拉伯核苷
- 细胞移植
- 基于细胞和组织的治疗
- 生物疗法
- 苯丙氨酸
- 氨基酸,芳香族
- 氨基酸,环状
- 基因检测
- 遗传技术
- 遗传服务
- 诊断服务
- 硝酸化合物
- 尿素
- 硝基化合物
- 组织移植
- 环磷酰胺
- 阿糖胞苷
- 卡莫司汀
- 马法兰
- 依托泊苷
- 干细胞移植
- ibrutinib
- 药物基因组学测试
- 骨髓移植
其他研究编号
- NCI-2015-00668
- U10CA180821 (美国 NIH 拨款/合同)
- NCI-2015-00668 (注册表标识符:CTRP (Clinical Trial Reporting Program))
- BMT CTN 1201
- A051301 (其他标识符:CTEP)
- A051301
- A051301 (其他标识符:Alliance for Clinical Trials in Oncology)
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.